Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis
In HCC patients with PVTT, SBRT had a better survival benefit than Lenvatinib treatment as first-line therapy.
Authors
- Xiaoquan Ji
- Quan Wang (ORCID: https://orcid.org/0000-0002-2821-5017)
- Aimin Zhang (ORCID: https://orcid.org/0000-0002-5311-7021)
- Xuezhang Duan
Institutions
- Chinese PLA General Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Radiation Oncology
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1186/s13014-024-02527-1
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- National Natural Science Foundation of China